Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2016 Aug 19;17(1):102.
doi: 10.1186/s12931-016-0413-9.

How to achieve safe, high-quality clinical studies with non-Medicinal Investigational Products? A practical guideline by using intra-bronchial carbon nanoparticles as case study

Affiliations
Review

How to achieve safe, high-quality clinical studies with non-Medicinal Investigational Products? A practical guideline by using intra-bronchial carbon nanoparticles as case study

M Berger et al. Respir Res. .

Abstract

Background: Clinical studies investigating medicinal products need to comply with laws concerning good clinical practice (GCP) and good manufacturing practice (GMP) to guarantee the quality and safety of the product, to protect the health of the participating individual and to assure proper performance of the study. However, there are no specific regulations or guidelines for non-Medicinal Investigational Products (non-MIPs) such as allergens, enriched food supplements, and air pollution components. As a consequence, investigators will avoid clinical research and prefer preclinical models or in vitro testing for e.g. toxicology studies.

The aim of this article is to: 1) briefly review the current guidelines and regulations for Investigational Medicinal Products; 2) present a standardised approach to ensure the quality and safety of non-MIPs in human in vivo research; and 3) discuss some lessons we have learned.

Methods and results: We propose a practical line of approach to compose a clarifying product dossier (PD), comprising the description of the production process, the analysis of the raw and final product, toxicological studies, and a thorough risk-benefit-analysis. This is illustrated by an example from a human in vivo research model to study exposure to air pollutants, by challenging volunteers with a suspension of carbon nanoparticles (the component of ink cartridges for laser printers).

Conclusion: With this novel risk-based approach, the members of competent authorities are provided with standardised information on the quality of the product in relation to the safety of the participants, and the scientific goal of the study.

Keywords: Good clinical practice; Good manufacturing practice; Guidelines; Intervention studies; Legislation; Non-medicinal products.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Overview of investigational products
Fig. 2
Fig. 2
Transmission Electron Microscopic (TEM) image of Printex-U. A cluster of particles with a primary particle size of < 50 nm is shown

Similar articles

Cited by

References

    1. European Commission. Clinical trials-Directive 2001/20/EC of the European Parliament and of the Counsil. In: Official Journal of the European Union. 2001. ec.europa.eu/health/files/eudralex/vol-1/dir_2001_20_en.pdf
    1. Ministry of Health WaS. The Medical Research Involving Human Subjects Act (WMO). 1998. http://wetten.overheid.nl/BWBR0009408
    1. U.S. Food and Drug Administration. Clinical Trials Guidance Documents. 2012. http://www.fda.gov/ScienceResearch/SpecialTopics/RunningClinicalTrials/u....
    1. U.S. Food and Drug Administration. Federal Food, Drug and Cosmetic Act. 1906. http://www.fda.gov/regulatoryinformation/legislation/ucm148690.htm.
    1. World Medical Association. Declaration of Helsinki. Ethical Principles for Medical Research involving Human Subjects. 1964. http://www.wma.net/en/30publications/10polecies/b3/index.html. - PubMed

MeSH terms

LinkOut - more resources